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SHORT REPORT
Paraneoplastic ophthalmoplegia and subacute motor
axonal neuropathy associated with anti-GQ1b
antibodies in a patient with malignant melanoma
L Kloos, P Sillevis Smitt, C W Ang, W Kruit, G Stoter
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A 68 year old woman developed oculomotor paresis
shortly after metastatic progression of her melanoma was
discovered. She was then immunised with the tumour anti-
gen MAGE-3 in combination with an immunological adju-
vant. During immunisation her symptoms worsened and
she developed severe, predominantly proximal axonal
motor neuropathy and became bedridden. IgM antibodies
against gangliosides GM2, GD3, and GQ1b were
detected in serum obtained two weeks before and nine
weeks after the onset of symptoms. Immunohistochemi-
cally, the patient’s IgM reacted with the tumour and
co-localised with GQ1b. She improved neurologically fol-
lowing steroid treatment and became ambulatory.
Malignant melanoma is a potentially immunogenictumour, and the development of melanoma vaccineshas been an important line of research. Tumour
specific antigens used as targets of melanoma immunotherapy
are often surface glycoproteins that share immunogenic simi-
larities with glycoproteins on the surface of normal melano-
cytes and cells in the central and peripheral nervous systems.
The immune response against these melanoma antigens may
also cross react with normal melanocytes or neurones, result-
ing in several clinical symptoms such as vitiligo, inappropriate
secretion of antidiuretic hormone (SIADH), and chronic
inflammatory demyelinating polyneuropathy (CIDP). We
describe a patient with malignant melanoma who developed
oculomotor paresis followed by a subacute motor axonal neu-
ropathy associated with antiganglioside antibodies suggesting
cross reactivity (“molecular mimicry”) between melanoma
and peripheral nerve antigens.
CASE REPORT
The patient had been diagnosed with a malignant melanoma
on her left foot in 1983. This was surgically excised (Breslow
thickness 1.9 mm). In March 2000, at the age of 68, she com-
plained of night sweating and weight loss of 17 kg over the
previous six months. Computed tomography (CT) showed
extensive retroperitoneal and left iliac lymphadenopathy. A CT
guided biopsy of an iliac lymph node was undertaken and
pathological examination showed malignant melanoma.
Reverse transcriptase polymerase chain reaction (RT-PCR)
showed tumour expression of the tumour antigen MAGE-3,
and the patient was included in an immunotherapy trial. The
treatment consisted of three intramuscular vaccinations at
weekly intervals with 300 µg MAGE-3 recombinant protein in
combination with immunological adjuvant.
In June, one week before the first vaccination, she
developed double vision. Two weeks later she was referred to
the neurology clinic. Examination revealed fluctuating exter-
nal ophthalmoplegia. Motor and sensory examination was
normal apart from absent deep tendon reflexes.
One month later (five weeks after the first vaccination), she
developed rapidly progressive and predominantly proximal
motor weakness:MRC muscle strength grade 3 in the deltoids
and hip flexors, grade 4 in biceps and triceps, and grade 5 dis-
tally; weakness in the neck flexors was MRC grade 2. Sensory
examination remained normal. The patient was admitted to
our hospital for further investigation.
Cranial and spinal magnetic resonance imaging (MRI)
before and after gadolineum administration was normal. The
CSF was acellular with raised protein (1.9 g/l) and repeatedly
negative cytology (on six occasions). Other laboratory studies
were unremarkable including creatine kinase, calcium, and
thyroid function studies. The erythrocyte sedimentation rate
was 68 mm/hour. Antibodies to acetylcholine receptor and
voltage gated calcium channels were negative and no antibod-
ies were detected against the paraneoplastic Hu, CV-2, Ri, Yo,
or amphiphysin antigens. A neostigmine provocation test pro-
duced no improvement in her symptoms. Electrophysiological
studies showed normal motor and sensory nerve conduction
velocities with normal or only mildly decreased motor ampli-
tudes. There were no signs of dispersion or conduction block.
Needle electromyography showed widespread acute denerva-
tion changes in the proximal muscles and mild denervation in
the distal muscles. Low frequency (3 Hz) and high frequency
(20 Hz) repetitive nerve stimulation did not change the com-
pound muscle action potentials. Because of the proximal dis-
tribution of the weakness, a deltoid muscle biopsy was taken.
Pathological examination did not show myelitis or myopathy.
Sural nerve biopsy showed signs of axonal degeneration with-
out inflammatory cells or immunoglobulin deposits.
The MAGE-3 vaccinations were stopped and she was
treated with intravenous immunoglobulin (0.4 g/kg/d for five
days). Despite this, her weakness deteriorated and she devel-
oped dysphagia and dysarthria. Subsequent steroid treatment
(20 mg dexamethasone daily) resulted in a remarkable
improvement in strength and bulbar function within two
days. She was discharged from hospital on 12 mg dexametha-
sone a day with a gradual taper. There was continuing
improvement in her symptoms and after six weeks she was
able to walk again without help. Because of relapsing diplopia
she was treated with five plasma exchanges, resulting in sub-
jective improvement. She has remained steroid dependent
(dexamethasone 6 mg/d).
METHODS
Serum samples were obtained from the patient two weeks
before the onset of symptoms (three weeks before the
vaccination was started) and nine weeks after the onset of
symptoms (eight weeks after the vaccination) . Both samples
were analysed for the presence of antiganglioside antibodies
against GM1, asialo-GM1, GM2, GM3, GD1a, GD1b, GD3,
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GT1b, and GQ1bwith an enzyme linked immunosorbent assay
(ELISA) and confirmed with thin layer chromatography as
described before.1 Serum was also tested for the presence of
IgM and IgA antibodies against Campylobacter jejuni, cytomega-
lovirus, Epstein-Barr virus, and Mycoplasma pneumoniae, as
described.2 Indirect immunofluorescent examination was
undertaken on formalin fixed, paraffin embedded sections of
the primary melanoma and the metastasis.3 In brief, the sec-
tions were prepared for double immunofluorescent labelling
by microwave preparation (five minutes at 900 W) in citric
acid (pH 6) followed by five minutes of 0.1% pronase
treatment at 37°C. The patient’s serum was diluted 1:200 and
polyclonal rabbit anti-GQ1b, R2327E4 diluted 1:100 was
added, followed by rhodamine and fluorescein labelled
secondary antibodies. Antibody specificity was determined by
incubation with a non-immune serum and by leaving out the
primary serum. Images were analysed and photographed
using a confocal fluorescent microscope.
RESULTS
Thin layer chromatographic overlay of the patient’s serum to
multiple purified gangliosides revealed strong and specific
binding of IgM with GM2 (titre 200), GQ1b (titre 400), and
GD3 (titre 200). The patient’s serum did not react with the
gangliosides asialo-GM1, GM1, GM3, GD1a, and GT1b. Weak
background reactivity with GD1b was observed. The titres of
the pre- and postvaccination samples (obtained two and nine
weeks after the onset of symptoms, respectively) were the
same. There was no IgG reactivity with any of the gangliosides
tested. The patient’s serum did not contain monoclonal bands
as determined by immunoelectrophoresis. No evidence for
recent infection with Campylobacter jejuni, cytomegalovirus,
Epstein-Barr virus, or Mycoplasma pneumoniae could be
detected.
On indirect immunofluorescence, the patient’s IgM reacted
with many of the tumour cells, as shown in fig 1A (fluorescein
filter). Antiserum to GQ1b reacted withmany of the same cells
(fig 1B), as visualised with the rhodamine filter. Co-
localisation is confirmed with double exposure in yellow (fig
1C).
DISCUSSION
The patient presented with external ophthalmoplegia in com-
bination with areflexia and a high CSF protein concentration,
with a normal CSF cell count and anti-GQ1b antibodies. She
subsequently developed a severe subacute motor axonal neu-
ropathy which made her bedridden within two months and
was accompanied by involvement of the lower cranial nerves.
The patient’s neuropathy developed shortly after the
diagnosis of recurrent melanoma and before vaccination, sug-
gesting a paraneoplastic aetiology. Neither ophthalmoplegia
nor subacute motor axonal neuropathy has previously been
reported as paraneoplastic syndromes associated with
melanoma.5 In this patient, other cancer related causes such as
leptomeningeal metastases and direct invasion of the periph-
eral nerves by the tumour were excluded.
Most paraneoplastic neurological syndromes are considered
autoimmune disorders caused by an immune response
directed against antigens in the tumour which subsequently
(cross) react with the same or similar epitopes in the nervous
system. The patient had IgM autoantibodies in her serum
which reacted with the gangliosides GM2, GD3, and GQ1b. All
three antigens are immunogenic and are expressed on
Figure 1 The patient’s IgM immunoreacts with many of the tumour
cells visualised in green with fluorescein filters (panel A). Anti-GQ1b
antiserum co-localises with most of the same cells as shown in red
with rhodamine filters (panel B). Co-localisation is confirmed in
yellow (panel C) by double exposure from the superimposition of red
and green.
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melanoma tumours and cell lines, suggesting that the tumour
may have triggered the production of antibodies. Indeed, the
patient’s IgM also reacted with the melanoma tissue,
co-localising with GQ1b. An immune aetiology of the
neuropathy is further suggested by the remarkable, albeit par-
tial, response to steroid treatment.
The importance of each of the target glycolipids for the
pathophysiological mechanism remains unclear. Anti-GQ1b
reactivity is strongly associated with oculomotor symptoms in
patients with immune mediated neuropathies.6 Moreover, in
20% of patients with Guillain-Barré syndrome and anti-GQ1b
antibodies, the EMG changes are mainly axonal, as in our
patient.7 In vitro models have clearly shown that anti-GQ1b
antibodies disrupt the neuromuscular junction, resulting in
breakdown of axonal terminals; this suggests that they can be
pathogenic in vivo.8 Anti-GM2 IgM antibodies can also affect
neuromuscular transmission.9 A pathogenic role of these anti-
bodies in our patient is less likely, because anti-GM2 antibod-
ies are associated with demyelinating neuropathies and their
specificity is questioned. Anti-GD3 antibodies most probably
result from cross reactive epitopes with GQ1b.
Other forms of neuropathy have been described in
association with melanoma, including five reported cases of
chronic inflammatory demyelinating polyneuropathy
(CIDP).3 10 A further pathophysiological relation between
melanoma and neuropathy is suggested by reports of
demyelinating neuropathy following vaccination with
melanoma lysates.11 In contrast to the previously reported
cases, the neuropathy in our patient was strictly motor,
axonal, and accompanied by upper and lower cranial nerve
involvement.
The relation between the vaccinations and worsening of the
neuropathy remains unclear. A direct relation with immunity
directed against MAGE-3 is highly unlikely because MAGE-3
is a tumour specific antigen that is not expressed in the nerv-
ous system.12 Furthermore, the neuropathy and antiganglio-
side antibodies were clearly present before vaccination, and
the titres of the antibodies were not influenced by the
vaccinations. It is difficult to conclude whether the evolution
of symptoms was spontaneous, or whether concomitant
vaccination played an indirect role. Clearly, stimulation of the
immune system—whether through an infectious process or
through vaccination—could theoretically promote auto-
immune phenomena by causing a systemic increase of
inflammatory cytokines. Although there is no evidence that
MAGE-3 vaccination caused the worsening of the neuropathy,
our observation suggests the need for caution when inducing
immune responses in patients with ongoing autoimmune
symptoms.
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CORRESPONDENCE
The naming of parts
Many deplore the journalistic trend to label
well recognised conditions by acronyms, or by
recently invented names—commonly to no
useful purpose. Thus neurologists may not
welcome yet another two names, recorded in
past literature but not in general currency.
Umapathi et al give a most valuable and
timely review of the dropped head and bent
spine syndromes.1 But why perpetuate the
ungainly phrase head ptosis? Ptosis, Greek
piτωσις = falling, has traditionally been
applied only to the upper eyelid and to
prolapse of any of the viscera or of the breasts.
Head drop is short and its meaning is
unequivocal.
Camptocormia, Greek καµpiυλ = bent;
κορµος = trunk of a tree: but, like a few
others,2 Umapathi et al apply it to signify a
bent spine. Camptocormia was first an illness
occurring among soldiers in World Wars I and
II, and was regarded as a sign of hysteria.
Ankylosing spondylitis is a more frequent
cause. It is an ostentatious word that portends
something more mysterious than a bent back
or neck. To be similarly pretentious, can we
not survive without such euphuisms?
J M S Pearce
Anlaby, East Yorks, UK; jmsp@freenet.co.uk
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Head drop and camptocormia
The article by Umapathi et al1 in this journal
referred to the original use of the term camp-
tocormia by Souques in 1915,2 though func-
tional bent back was first described by Brodie
in 1837. Mlle Rosanoff-Saloff supported Sou-
ques’ case study with a photographic record
of this soldier’s bent back and his recovery.
According to the English translation abstract
in Southard’s fine collection of shell shock
cases3 this soldier was wounded five months
previously by a bullet that entered along the
auxiliary border of the scapula and emerged
near the spine. “He spat blood for several days
... and when he got up his trunk and thighs
were found to be in a state of moderate flex-
ion upon the pelvis, the trunk being bent
almost at a right angle.” He was able to bend
his trunk still further forward than ‘its
habitual contractured position’ and it was
evident that there was contraction of the
muscles of the abdominal wall and of the ili-
opsoas. “No motor, sensory, reflex, trophic,
vasomotor, electrical, visceral or X-ray disor-
ders could be found.” The application of plas-
ter corsets ‘cured’ this man’s deformity
within six weeks.
The poilus spoke of this condition as
cintrage (arching), suggesting that it was not
an uncommon affliction of the French
soldier. Seemingly only recorded by French
neurologists, Roussy and Lhermitte reported
two subsequent cases.3 An infantryman
was thrown into the air by the bursting of a
shell, rendered unconscious and recovered
experiencing violent pains in the back. He
remained stooped to the right. His bent back
was corrected by the application of plaster
corsets. The other reported case was that of a
chasseur who was buried in an explosion,
knocked unconscious, and experienced
acute respiratory distress, and subsequent
mutism and camptocormia. One séance of
electrical treatment corrected the improper
attitude of the trunk, though he did continue
to experience “a few persistent lumbar
pains”.
It would be difficult to doubt the probabil-
ity that psychological factors influenced
these men’s recuperation. To describe these
soldiers as hysterical,1 though this was the
terminology used during this period, or
indeed that they suffered functional bent
back, is probably unfair. They may well have
suffered acute traumatic spinal injury and
reactive muscle spasm (and contractures).
Persistent stooping in shallow trenches, in
appalling conditions of deprivation and dan-
ger, may have been contributing factors
weakening the tone of paraspinal muscles.
However, these case reports suggest that the
traumatic injury alone may be sufficient
explanation for the bent spines. The manage-
ment of camptocormia in the first world war
was to provide biomechanical supports, such
as corsets, apparently with good results. The
psychological therapies of “persuasive re-
education” were additive rather than pivotal,
and faradisation (and other tortures) used
only “if necessary”.3
The Sandler triad of low self esteem
with confusion of identity, sadomasochistic
behaviour toward military authorities, and
impotence4 were, in 1947, proposed as being
an essential part of camptocormia.
Umapathi’s1 recognised causes of campto-
cormia and the contributing factors however
implicate organicity, as indeed do the original
case reports.
A D Macleod
Psychiatric Consultation Service, Christchurch
Hospital, Private Bag 4710, Christchurch, New
Zealand; PCS@cdhb.govt.nz
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Author’s reply
We would like to thank Dr J M S Pearce for his
comments.
We agree with him on the proliferation of
medical terms referring to similar if not iden-
tical conditions. One of the chief aims of writ-
ing this paper is to thread a line of common-
ality through the various names in literature,
which in essence refer to an anterior curva-
ture of the spine. Hence the title “Head drop
and camptocormia, the spectrum of bent-
spine disorders”.
However, we would like to disagree with Dr
Pearce labelling the spinal deformity seen in
ankylosing spondylitis as camptocormia. In
arthritic conditions and diseases that affect
bone, the spinal deformity is fixed. In the
bent-spine disorders referred to in the paper,
the deformity may reduce considerably or
even disappear with change in position, for
example when supine. We would therefore
prefer to reserve the phrases head drop (used
interchangeably with head ptosis) and camp-
tocormia to neurological conditions that
affect the strength or tone of the muscles con-
trolling spinal posture.
As aficionados of medical history, we very
much enjoy Dr A D Macleod’s letter. We agree
that organic factors might have contributed to
the camptocormia in solders believed to have
been suffering from hysteria. It would have
not been unexpected for patients, like the
man described by Southard with a bullet
wound near the spine,1 to have developed
spasm or even denervation of thoracic par-
aspinal muscles.
T Umapathi
Department of Neurology, National Neuroscience
Institute, 11 Jalan Tan Tock Seng, 308433
Singapore; tumapathi@yahoo.com
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Infection and multiple sclerosis
The article by Hawkes1 and the editorial com-
mentary about the role of infectious agents in
multiple sclerosis (MS) examined this ques-
tion from a new viewpoint based on epide-
miological observations.2 Several infectious
agents, most not sexually transmitted, were
reported to be associated with MS according
to epidemiological data, serology in CSF and
blood, or demonstration of pathogens in
tissue. A relation with measles virus (MV)
has been an early and most consistent
finding. More recently, higher prevalence and
higher titres of antibodies against human
herpesvirus 6 (HHV6), but not other
herpesviruses, were shown in MS patients
compared to control groups, suggesting dif-
ferent exposure to HHV6 in MS.3 HHV6, like
vaccine strain MV and certain wild type MV,
uses the membrane cofactor protein (MCP;
CD46) as a receptor for entry into cells. This
suggests a possible involvement of CD46 in
MS.
The possibility of a particular isoform of
CD46 predisposing MS patients to infection is
unlikely because all isoforms have similar
affinity to MV. Increased levels of soluble
CD46 have been reported in the serum and
cerebrospinal fluid of MS patients, more in
those who have HHV6 DNA.4 One interpret-
ation of these findings involved increased
activity of the complement system in MS.
However, experimental studies show no
influence of inflammatory cytokines on CD46
expression and do not support inflammation
J Neurol Neurosurg Psychiatry 2003;74:692–694692
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as a cause of increased CD46.5 Incorporation
of CD46 in the viral envelope, or a possible
genetic propensity in MS patients, have also
been considered as causes of increased
CD46.4 While its origin in MS is unclear, solu-
ble CD46 might be involved in viral pathogen-
esis by binding the virus in the viraemic
phase and allowing another to attach to CD46
and spread from cell to cell. Both HHV6 and
MV are infectious agents encountered in
early childhood, and HHV6 can indeed
become reactivated a few weeks after primary
MV infection. On the other hand, because
HHV6 and MV downregulate CD46 expres-
sion on the infected cell, they may diminish
the entry of each other, delaying the time of
infection. Therefore, they might produce
increased antibody levels in young adults
through delayed infection with, or reactiva-
tion of, each other. These suggest increased
antibodies against these two viruses in MS
may be interrelated.
The question remains whether a cause-
effect relation exists between infectious or-
ganisms and MS, or whether viruses are just a
consequence of the activation of the
inflammatory-immune sequence or increased
susceptibility of MS patients to infection.
Studies of CD46 and other viral receptors
seem warranted in MS.
B Anlar
Department of Pediatric Neurology, Hacettepe
University, Ankara 06100, Turkey;
banlar@hacettepe.edu.tr
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Infection and multiple sclerosis
The paper by C H Hawkes (Is multiple sclero-
sis a sexually transmitted infection?1) has
caused predictable distress to people with
multiple sclerosis (MS) and their families.
Living with MS is a difficult enough experi-
ence without such sudden and avoidable
alarm. The UK Multiple Sclerosis Society’s
national helpline and local branches have
been inundated with calls expressing anger
and anxiety.
It is hard to understand the motive for pub-
lication when your own expert editorial com-
mentator specifically referred to the paper’s
“pure speculation” and “potential to cause
harm”. Did the sensational nature of Dr
Hawkes’s hypothesis and the virtual guaran-
tee of extensive publicity it could receive out-
weigh proper consideration of its scientific
merit?
There is also the worrying question of what
damage may have been caused to the reputa-
tion of MS research in the UK by the lay
media coverage which was attracted. The MS
Society has a current forward commitment of
around £12 million to nearly 70 research
projects. That money is raised by voluntary
donation. Anything which could discredit the
quality of research here is of material concern
to us.
M O’Donovan
Chief Executive, The Multiple Sclerosis Society, M S
National Centre, 372 Edgware Road, London
NW2 6ND, UK; modonovan@mssociety.org.uk
Reference
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Ed: The journal regrets any distress caused to
patients with MS as a result of the widespread
publicity this article received in the media.
However, we wish to emphasise that the article was
subject to the usual peer review process.
BOOK REVIEWS
Delirium in old age
Edited by J Lindesay, K Rockwood, A
Macdonald (Pp 238, £55.00). Published by
Oxford University Press, Oxford, 2002. ISBN
0-19-263275-2
Delirium is an extremely important condition
for a number of reasons. It is very distressing
and frightening for those who experience
the symptoms, and descriptions of the effects
on the brain as a result of high fever
have been well described. There is a high
mortality associated with the development of
delirium, and it is often associated with
behavioural disturbances that can be trouble-
some for carers and attendants. Finally, it
presents a unique opportunity to look at the
interface between psychiatric symptoms
caused by organic disease and functional dis-
orders.
Twelve years ago, the same publishers
and two of the current editors produced the
first edition on delirium. It was a relatively
thin book but set the standards that
the current edition continue. Delirium is cer-
tainly a niche market, and there appear
to be no direct competitors, although text-
books on old age psychiatry usually contain
chapters and notes on delirium. The new edi-
tion is greatly expanded and very much up to
date.
Every aspect of delirium is included, from
the history and conceptual basis of the disor-
der through epidemiology, neurophysiology,
clinical assessment, management, preven-
tion, and, refreshingly, the the role of family
caregivers and nurses in managing the
disease. The core tenet of the book is that
delirium is a disorder that is relatively poorly
recognised (particularly the hypo-alert type)
by the general clinical professions, it is
relatively easy to identify people at risk of
developing delirium, and that there is a
real possibility of a reasonable preventive
strategy for the disorder. Twelve authors have
contributed and, as delirium is relatively
under-researched, this probably represents a
significant proportion of the leading
researchers in the field internationally.
There are particularly interesting sections
on the conceptual basis of the disorder
and how it, and its component symptoms,
are defined, methods of assessment of
delirium are covered comprehensively, a
summary of how evidence based manage-
ment plans can be developed, and the
prospects of prevention of delirium are given
an adequate airing.
An interesting spin, which I discovered by
accident, is that on the Oxford University
Press website (www.oup.co.uk), one can
see online updates of each individual
chapter. Those present when this author
last visited the website (December 2002)
consisted of work that had been done from
when the manuscript had been submitted to
publication. It may be that reviews of
the book might also appear online—this one
will.
The book is a landmark in the literature on
delirium, is a text of very high quality, and
anyone seriously involved in the clinical
management of patients with delirium or
research on the subject would do very well to
read this book.
A Burns
Neurophysiology in
neurosurgery. A modern
intraoperative approach
Edited by Vedran Deletis and Jay L Shils (Pp
469, $125.00). Published by Academic
Press, California, 2002. ISBN 0-12-
209036-5
This book comprises 17 chapters contributed
by 24 authors. It has clearly benefited from
most of the chapters being written in a more
or less homogenous style and formed
into seven parts based mainly on surgical
procedures: motor evoked potentials/
neurophysiological base; intraoperative
neurophysiology (ION) of the spinal (spinal
cord monitoring); ION of peripheral nerves,
nerve roots and plexuses; ION of cranial nerve
and brainstem; ION of supratentorial proce-
dures; ION during stereotactic neurosurgery
for movement disorders; and ION and anaes-
thesia management. Most of the chapters
cover the background of methodology, de-
scription of the surgical procedure, and the
related neurophysiological procedure, per-
sonal experience, and case reports, which
gives a balanced theoretical and practical view
on the topic of each chapter. The interdiscipli-
nary approach taken in this book will ensure
it has a wide range of readers across
“neurosurgery, neurology, orthopaedic sur-
gery, neurophysiology, anesthesiology, inter-
ventional radiology, and biomedical engineer-
ing”.
Chronic deep brain stimulation or neuro-
modulation has extended the role of clinical
neurophysiology beyond its traditional diag-
nostic role. This new field is touched upon
briefly in the part on ION during stereotactic
neurosurgery. An interesting feature of this
book is that it is accompanied by a CD that
certainly enhances its value. Cross references
are given at the end of the corresponding
chapter rather than in the list of contents
in the book, and at the front page of the
display.
In conclusion, it is an authoritative review
of intraoperative neurophysiology much
weighted on the motor system for a wide
range of surgical procedures. Perhaps, in its
present form, those hoping for a more
systematically informed discussion on
intraoperative neurophysiology of the sensory
system may feel slightly disappointed.
X Liu, T Z Aziz
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Clinical neurophysiology of the
vestibular system, 3rd edition
Edited by R.W. Baloh and V. Honrubia (Pp
408, US$98.50). Published by Oxford Uni-
versity Press, New York, 2001. ISBN 0-19-
513982-8.
The first edition of Clinical neurophysiology of the
vestibular system, published in 1979, had a
significance beyond its content: it affirmed
that neurology had a stake in the vestibular
system. Here was a neurologist (Baloh)
writing with an otolaryngologist (Honrubia)
about semicircular canals, endolymph, audio-
grams, and above all the vestibulo-ocular
reflex—the “VOR”. The VOR is no ordinary
reflex; one can measure accurately both its
input and its output and come up with a
transfer function for gain—a new concept
then for neurology. We have learnt a lot more
about measurement of vestibular function
and about disorders of the vestibular system
since 1979. The 2nd edition, published in
1990, and now the third edition, incorporate
these advances.
And what a terrific book it still is: based on
concepts, packed with facts, lucidly written,
and rigorously referenced. Its structure is
logical and its language is clear, so that it is
not only easy to search and browse but a
pleasure to read from cover to cover. And it is
comprehensive—no vestibular stone is left
unturned.
There are four main parts, dealing in turn
with: the structure and function of the
vestibular system (four chapters); the clinical
and laboratory evaluation of the dizzy patient
(four chapters); specific diseases affecting the
vestibular system (10 chapters); and the
treatment of vertigo and vestibular loss (two,
yes only two, chapters—but then that’s
neurology for you).
It’s impossible to single out any one chapter,
they are all outstanding. For example, I
particularly liked the new material in chapter
one on the phylogeny of the vestibular system.
Now one would have to admit that familiarity
with the otocyst of the sea anemone is not a
lot of use in the consulting room, but this sec-
tion is so clearly written and matter so inter-
estingly explained that one happily dispenses
with such utilitarian demands.
The great strength of the book and what
has made it such a classic, is that although it
is based on physiology, full comprehension of
physiology is not a prerequisite for retrieving
useful information from the disease based
chapters. Although the structure is there, one
can put this aside and simply delve. The chap-
ters on the three most common vestibular
diseases, benign positional vertigo, migraine,
and Meniere’s diseases, are absolute gems.
Each could be published as a self-contained
review in its own right.
The book is an elegant conceptual and fac-
tual account of the vestibular system, its
disorders and diseases, rather than a self-help
or how I do it manual. Some readers might
miss not having, a “frequently asked clinical
questions” section, or at least a “frequently
encountered clinical pitfalls” section, but then
no one can have it all. Anyone who sees dizzy
patients needs one dizzy book on the desk.
This is the one I have on mine.
G M Halmagyi
Role of proteases in the
pathophysiology of
neurodegenerative diseases
Edited by Abel Lajtha and Maren L Banik (Pp
302, £59.50). Published by Kluwer
Academic/Plenum Publishers, New York,
2001. ISBN 0-306-46579-5
This volume would be an extremely useful
addition to the bookshelf of anybody with an
active interest in the biochemical and patho-
logical processes that underlie some of the
more common neurological diseases. In the
past the role of proteolysis in these disorders
has been largely neglected because it was
assumed that it represented a general non-
specific metabolic process. In terms of attract-
ing research interest the field also suffered
from the confusion in the literature concern-
ing the naming of these enzymes and the fact
that the same enzyme might have many
different names. However, as the editors point
out in their preface, this is no longer the case
and they have managed to bring together an
impressive array of current research on the
involvement of proteases in a wide variety of
disorders. From what individually might have
been regarded as rather disparate studies, one
can now start to see common themes not least
of which is the potential therapeutic value of
targeting specific proteases and the develop-
ment of specific inhibitors.
If, like me, you don’t have specialist knowl-
edge of this area I would recommend going
straight to the last chapter on the mammalian
proteinase genes. Here you will find a clearly
laid out summary of the classification and
characteristics of the four main groups of pro-
teases (serine, cysteine, aspartic, and metallo-
proteinases). I also found the chapter on the
ubiquitin/proteasome system and the normal
physiological breakdown of proteins particu-
larly informative. Having read these two
chapters you then have a wide choice of disor-
ders and proteases to choose from. Perhaps
the most widely discussed is Alzheimer’s dis-
ease, undoubtedly because of the huge ad-
vances that have been made in the under-
standing of the biochemical processes
underlying this disease over the past 15 years.
Papain-like cysteine proteases (cathepsins),
caspases, calpains, and a novel metallo-
endopeptidase (EC 3.4.24.15) all appear to
have some role in the pathology of
Alzheimer’s disease and may, therefore, be
potential targets for drug development. There
is also a group of Alzheimer’s disease specific
proteases that affect the processing of the
amyloid precursor protein (α, β, and, γ
secretase) and presenilin (presenilinase).
Both of these proteins are central to the
development of pathology and so these
enzymes in particular are key targets for cur-
rent drug company research.
Apart from the interest in Alzheimer’s
disease, there are other chapters covering the
role of matrix metalloproteinases and calpain
in the demyelination of multiple sclerosis and
the key role of calpain in the pathology of
traumatic brain and spinal cord injury.
Further chapters describe the loss of calcium
homeostasis and the subsequent pathological
activation of calpain, resulting in the break-
down of key structural proteins in some
neuromuscular disorders. In summary, this
book has something for everyone in an area of
research that holds huge promise for the
future in terms of developing useful therapies
for treating neurodegenerative disorders.
S Gentleman
CORRECTIONS
The following abstract was not printed with
the article by E L J Hoogervorst, M J Eikelen-
boom, B M J Uitdehaag, and C H Polman (One
year changes in disability in multiple sclerosis:
neurological examination compared with pa-
tient self report) in the April issue of JNNP
(JNNP 2003;74:439–42).
Objective: To characterise the relation
between one year changes in neurologist rat-
ing of neurological exam abnormalities as
measured by the EDSS and changes in patient
perceived disability as measured by the GNDS
in patients with MS.
Methods: 250 patients with MS were
recruited at an outpatient clinic. Disability at
baseline and one year follow up was assessed
using the EDSS and GNDS. Correlations
between change in EDSS, GNDS-sum score,
functional systems, and GNDS subcategories
were studied as well as the significance of
changes in EDSS associated with changes in
perceived disability.
Results: The correlation between one year
changes in EDSS v GNDS was substantially
lower (0.19) than cross-sectional correlations
between EDSS and GNDS, either at baseline
(0.62) or at follow up (0.77). Notably, changes
in functional system scores that are based on
neurological examination are poorly or not at
all correlated with changes in disability as
perceived by the patient. Analysing the impact
of a significant worsening in EDSS score we
found that this was associated with signifi-
cant worsening, insignificant change, and sig-
nificant improvement in the patients’ per-
ceived disability in 45%, 39%, and 15% of
patients, respectively.
Conclusion: Patients’ perception of change
in disability differs not only quantitatively but
also qualitatively from that of an examining
physician. There are true differences in
change as perceived by the patient and
measured by the physician and changes in
many dimensions of disability are relevant to
the patient and have no measurable impact on
the EDSS.
The authors of the short report entitled Para-
neoplastic ophthalmoplegia and subacute
motor axonal neuropathy associated with
anti-GQ1b antibodies in a patient with malig-
nant melanoma, published in the April issue
2003 of JNNP (2003;74:507–9), were listed in
the incorrect order. The author order should
read as follows: L Kloos, C W Ang, W Kruit, G
Stoter, and P Sillevis.
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